HDL

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

Retrieved on: 
火曜日, 5月 28, 2024
Apolipoprotein AI, LDL, Juntendo University, SAFETY, ATP, Patient, Cardiovascular disease, Fats, Oxysterol, Human, Lipid metabolism, EAS, CERP, ABCG1, Liver, ABCA1, Messenger, SAE, MD, Congress, NAFLD, Qi, Macrophage, DMSO, Abstract, Tokyo Stock Exchange, Leukemia, LXR, HDL, Cell, Apo, ABCA, Research, Liposome, Cholesterol, PKA, Code, Vaccine

As of 25 April 2024, 33 patients were enrolled, 19 patients were randomized, 14 patients completed the study.

Key Points: 
  • As of 25 April 2024, 33 patients were enrolled, 19 patients were randomized, 14 patients completed the study.
  • Three subjects reported serious adverse events (SAE) and were all considered “Unlikely related” or “Unrelated“ to study drug.
  • Objectives of this study are to evaluate the effects of MN-001 and its major active metabolite MN-002 on cholesterol efflux capacity in THP-1 *1macrophages.
  • ABCG1 also effluxes cholesterol to low-density lipoproteins (LDL), liposomes and cyclodextrin and it exports sphingomyelin, phosphatidylcholine and oxysterols to HDL and albumin.

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia

Retrieved on: 
火曜日, 5月 28, 2024
Research, General Health, Pharmaceutical, Infectious Diseases, Genetics, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, Diabetes, Moyamoya disease, Patient, Baylor College of Medicine, Arrowhead, Triglyceride, EAS, APOC3, Risk, Hypertriglyceridemia, Apolipoprotein C-III, Apolipoprotein B, Lipoprotein, Congress, Week, ASCVD, HDL, Principal, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ARO-APOC3) in patients with mixed hyperlipidemia.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ARO-APOC3) in patients with mixed hyperlipidemia.
  • These data were presented in an oral presentation today at the European Atherosclerosis Society (EAS) 92nd Congress and simultaneously published in the New England Journal of Medicine .
  • “Despite advances in treatment, patients with mixed hyperlipidemia have elevated and persistent ASCVD risk due in part to high levels of atherogenic triglyceride rich lipoproteins.
  • Arrowhead is also presenting data from the SHASTA-2 study of plozasiran and the ARCHES-2 study of zodasiran (formerly ARO-ANG3) at EAS.

HdL Companies Reports Persistent Decline in California Sales Tax Returns in 4Q2023

Retrieved on: 
火曜日, 4月 16, 2024
Professional Services, Public Policy, Government, State, Local, Finance, Consulting, Accounting, Tax, Shoe, News, Golden, Federal, Federal Reserve, Growth, HDL, Anomaly

“Despite being the traditionally high-performing quarter, California's local one-cent sales and use tax receipts saw a marked decrease.

Key Points: 
  • “Despite being the traditionally high-performing quarter, California's local one-cent sales and use tax receipts saw a marked decrease.
  • This decline reflects consumer challenges balancing higher prices and financing costs with essential household needs,” reports Andy Nickerson, President/CEO of HdL Companies, the leading provider of revenue enhancement, technology, and consulting services for local governments.
  • Sales of general consumer goods faced lackluster results during the holiday shopping period, declining by 3.4%.
  • As the Federal Reserve considers a delay in softening rates, HdL Companies anticipates consumer spending may continue to stagnate, delaying a return to normal historical growth trends in 2024.

New Clinical Study Reveals Consuming 12 Eggland's Best Eggs Weekly Shows No Negative Effects on Cholesterol Levels; Study Also Suggests Possible Benefits for Some Consumers

Retrieved on: 
月曜日, 4月 8, 2024
Research, Health, LDL, Cardiovascular disease, Vitamin, Nutrient, Cardiology, Diabetes, Risk, Patient, Senior, American College, Clinical trial, HDL, Cholesterol, Egg as food, Duke, Vitamin B12, Pharmaceutical industry

CEDAR KNOLLS, N.J., April 8, 2024 /PRNewswire/ -- Americans are increasingly aware of the impact of cholesterol on heart health and well-being, but for decades, there have been conflicting headlines about which foods can have positive or negative effects. Eggs, in particular, have often received negative press related to cholesterol. However, a new study presented at the American College of Cardiology's Annual Scientific Session that was led by researchers at Duke and sponsored by Eggland's Best, offers promising new evidence on fortified eggs.

Key Points: 
  • The clinical trial studied 140 participants from a broadly generalized population who had a high risk of heart disease.
  • Researchers randomized participants into two groups, asking half to eat two or fewer eggs per week for four months.
  • Ultimately, the study found that over 4 months, eating Eggland's Best eggs resulted in no adverse effects on lipid profiles and markers of cardiovascular risk for these patients.
  • The consumption of Eggland's Best eggs may also increase Vitamin B12 levels, also helping to support a healthier lifestyle.

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

Retrieved on: 
月曜日, 3月 18, 2024
Diagnosis, Glucose, Histology, Adipose tissue, Arm, Glycated hemoglobin, Type 2 diabetes, Disease, Connective tissue, Steatosis, Insulin, Weight gain, Diabetes, CT1, Patient, Inflammation, SGLT2, Adiponectin, Table, MASH, MD, Liver injury, Insulin resistance, LEGEND, Fibrosis, HDL, Fatty liver disease, Empagliflozin, Safety, Euronext Paris, Phase, NASH, Hepatitis, Lipid metabolism, Prediabetes, Liver disease

Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.

Key Points: 
  • Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.
  • The treatment with lanifibranor 800mg/once daily alone or in combination with empagliflozin for 24 weeks was well tolerated, with no safety concerns reported.
  • The trial is double-blind for the placebo arm and lanifibranor (800mg daily) arm, and open-label for the combination of lanifibranor (800mg daily) and empagliflozin (10 mg daily) arm.
  • More details on these results are expected to be presented in upcoming scientific conferences and submitted for publication.

BLACK HEALTH MATTERS TO HOST FREE SPRING HEALTH SUMMIT AND EXPO IN WASHINGTON, D.C.

Retrieved on: 
水曜日, 4月 3, 2024
Kidney, Glucose, LDL, Exercise, Hepatitis C, Jabari, Black, BMS, National Pan-Hellenic Council, Patient, Vertex, Lunch, PSA, Legislation, Education, Gallaudet University, Omega Psi Phi, Incontinence, Johnson & Johnson, Cholesterol, WRC-TV, Triglyceride, Hypertension, Sanofi, Doctor of Pharmacy, Leukemia, Memory, Food, HDL, Phi Beta Sigma, Health, COVID-19 vaccine, Conference, BHM, COVID-19, All My Children, Howard University Hospital, Breakfast, Kidney disease, Diet, Guru, Sibley Memorial Hospital, Pharmaceutical industry

WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13. As part of the award-winning health summit series, the free, one-day event will be held at the Kellogg Conference Hotel at Gallaudet University at 800 Florida Avenue, N.E., Washington, DC 20002 and includes celebrity hosts, medical professionals, health screenings, prizes, breakfast, and lunch. The event is open to the public and will begin at 8:30 a.m. with breakfast and conclude at 3:30 p.m.

Key Points: 
  • Popular health-focused event to feature free screenings, conversations with experts and celebrities
    WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13.
  • After over a decade of hosting the popular health-focused summits, this will be the first in Washington, D.C. for Black Health Matters.
  • The Black Health Matters Spring Summit & Expo is sponsored by leading health organizations including Sanofi|Regeneron, Johnson & Johnson Health Care Systems, Johnson & Johnson Innovative Medicine, Research Includes Me, BMS, Sanofi, argenx, Vertex and CISCRP.
  • Notable partners are Howard University Hospital; DC Department of Health Care Finance; Precision Wellness; and American Association of Kidney Patients.

Healthy Foods Deliver Defense Against Cancer and Heart Disease

Retrieved on: 
水曜日, 2月 21, 2024
Buffalo, Blood pressure, Diabetes, Breast cancer, Consumer, Effect, Copper, Research, Magnesium, Zinc, Cholesterol, Blood, Obesity, Mineral, Food, Vitamin, Weight loss, Glycemic, Prostate, Plant, Harvard University, Purdue University, Conditional sentence, Exercise, Plaque, Human body weight, Phytosterol, Niacin, Risk, Potassium, Vitamin E, Seed, Types of plant oils, Radiation, Olive oil, Health, Folate, University, Death, Nutrient, Fasting, Medicine, Artery, Physiology, Heart, Resveratrol, Food industry, Pinterest, Meal, Brain, Fats, HDL, Cancer, Randomized controlled trial, Dietary supplement

The vitamins and minerals in "good-for-you" nourishment provide energy for daily living, help the body grow and repair and can prevent diet-related illnesses like cancer and heart disease.

Key Points: 
  • The vitamins and minerals in "good-for-you" nourishment provide energy for daily living, help the body grow and repair and can prevent diet-related illnesses like cancer and heart disease.
  • According to the Centers for Disease Control and Prevention, heart disease is the leading cause of death in the United States, followed by cancer.
  • There are a number of factors that can increase the risk of developing heart disease, including high blood pressure, high cholesterol, obesity and diabetes .
  • Research shows that in addition to inhibiting colon, prostate and breast cancer cell growth, they can also protect against heart disease.

The Next Evolutionary Step in Customizable Logic, Microchip Releases PIC16F13145 Family of MCUs

Retrieved on: 
水曜日, 1月 24, 2024
Core, IDE, Family, ADC, Logic, BOM, Configurator, CLC, Digital, Asymmetric multiprocessing, Microchip Technology, MCU, DAC, CLB, Hardware description language, MCHP, Module, CPU, HDL, SPI, MPLAB, I2C, Analog, MCC, Integrated circuit, CIP

Outfitted with a new Core Independent Peripheral (CIP)—the Configurable Logic Block (CLB) module—the MCUs enable the creation of hardware-based, custom combinational logic functions directly within the MCU.

Key Points: 
  • Outfitted with a new Core Independent Peripheral (CIP)—the Configurable Logic Block (CLB) module—the MCUs enable the creation of hardware-based, custom combinational logic functions directly within the MCU.
  • The process is further simplified by a graphical interface tool, which helps synthesize custom logic designs using the CLB.
  • The PIC16F13145 family is designed for applications utilizing custom protocols, task sequencing or I/O control to manage real-time control systems in the industrial and automotive sectors.
  • For additional information and to purchase, contact a Microchip sales representative, authorized worldwide distributor or visit Microchip’s Purchasing and Client Services website, www.microchipdirect.com .

Solutions for Testing Wireless, IP, Fiber Optics, Analog, and TDM Networks

Retrieved on: 
月曜日, 1月 22, 2024
Voice over IP, EVS, Digital, GPS, ATM, API, Switch, NVM Express, Land mobile radio system, HDL, GSM, PPP, GTP, Noise, IP, Communication, Wide area network, SONET, Wireless, ITU, APS, Drive, CAMA, PESQ, Google Maps, Computer network, CAS, Phonation, ISDN, CLI, FXO, Voice over LTE, SMS, Human, SS7, Automation, TDM, RAW, RFC, Human voice, Data-rate units, OC-48, IUP, 3GPP, POLQA, GPRS, Language, Solid-state drive, INAP, TCP, ATA, MAP, Frame Relay, Optical fiber, Analog, AMR, HTTP, Estrone, ISAC, Mobile phone

“GL Communications Inc. is a leading test and measurement equipment manufacturer for Wireless, IP, Fiber Optic, Analog and TDM networks.

Key Points: 
  • “GL Communications Inc. is a leading test and measurement equipment manufacturer for Wireless, IP, Fiber Optic, Analog and TDM networks.
  • GL also offers consulting services to design, implement, verify, and inspect communications systems including wireless, IP, satellite, fiber optic, digital, and microwave networks.
  • GL offers multi-functional Ethernet testers to test individual devices such as cables, switches, routers, as well as end-to-end Ethernet/IP networks.
  • The test tools operate at wirespeed (1/10/25/40/50/100 Gbps) and offer bit error rate testing, RFC 2544, ITU-T Y.1564 and RFC 6349 based TCP testing.

HdL Companies Reports Moderate Decline in Sales Tax Returns in California in 3Q2023

Retrieved on: 
月曜日, 1月 22, 2024
Supply Chain Management, Professional Services, Public Policy, Government, Retail, State, Local, Finance, Consulting, Federal, Housing, Golden State, HDL, Tourism, Travel, Federal Reserve, Transport

The Golden State reported a slight decrease in sales tax receipts in the third quarter of 2023, showing an overall decline of 1.6% compared to the same period in 2022.

Key Points: 
  • The Golden State reported a slight decrease in sales tax receipts in the third quarter of 2023, showing an overall decline of 1.6% compared to the same period in 2022.
  • “An 8% decline in receipts from service stations and petroleum providers contributed the most to the drop as consumers benefitted from lower prices at the pump.
  • This also dampened receipts from sellers of general consumer goods as those retailers selling fuel experienced a similar drop.
  • We also saw consumers pull back on large purchases,” stated Andy Nickerson, President/CEO of HdL Companies, the leading provider of revenue enhancement, technology and consulting services for local governments.